The positive results on RAAS targeting drugs in COVID-19 were further reinforced by the meta-analysis of Lu Ren and colleagues [145], which included 53 retrospective studies, for a total of 2,100,587 patients: hypertensive patients treated with ACE inhibitor/ARBs showed a lower risk of severe disease (odds ratio 0.81, 95% CI 0.66–0.99, p < 0.05) and death (odds ratio 0.81, 95% CI 0.66–0.99, p < 0.05), while no difference in COVID-19 incidence was observed. This evidence concerns the gene ACE and COVID-19.